# Wuhan Greenovo Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuhan-greenovo-biotechnology-co

- Industry: Medical Devices & Equipment
- Headquarters: Wuhan, China
- Website: www.gnovo.com
- Total disclosed funding: $6M
- Latest round: Series B (Dec 22, 2016)
- Investors on record: 4

## About

Established in 2012 and based in Wuhan, China. Wuhan Greenovo Biotechnology Co., Ltd. is a biomedical material manufacturer that focuses on hemostasis and wound care. In July 2015, the company raised CNY 10 million in series A funding. In August 2017, the firm was listed on the National Equities Exchange and Quotations. Its stock code is 871920. In October 2024, it raised CNY 99.99 million in venture funding.

The company provides medical care experience for clients such as medical staff, patients, medical research institutions and enterprises. The business of the company includes research and development, production and sales of new biomedical materials. The company's products include military first aid hemostasis, intraoperative hemostasis, wound care, dental hemostasis and home care. The company's products focuses on cardiovascular, anesthesiology and intensive care, general surgery.

The company’s revenue is generated by providing biomedical materials.

## Funding rounds

- Series B, Dec 22, 2016, $4.3M — Cher Ami Wealth & Financial, Cherami Investment Group
- Series A, Jul 20, 2015, $1.6M — Rivercity Investment, Guangzhou Cherami Sun Tour Equity Investment Management

## Investors

- Rivercity Investment (https://capitalatlas.ai/funds/rivercity-investment) — Series A
- Guangzhou Cherami Sun Tour Equity Investment Management — Series A
- Cher Ami Wealth & Financial — Series B
- Cherami Investment Group (https://capitalatlas.ai/funds/cherami-investment-group) — Series B